368 results on '"Kayser, Sabine"'
Search Results
2. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
3. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
4. Management of Acute Promyelocytic Leukemia
5. Prolonged Thrombocytopenia and Severe Transfusion Reaction after ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with Chronic Myelomonocytic Leukemia
6. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.
7. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease
8. International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: Summary
9. International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: Responses
10. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
11. Management of Acute Promyelocytic Leukemia
12. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis
13. P375: INOTUZUMB OZOGAMICIN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY ACUTE B-LYMPHOBLASTIC LEUKEMIA
14. PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
15. Management of Acute Promyelocytic Leukemia at Extremes of Age
16. Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
17. Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study
18. Management of patients with acute promyelocytic leukemia
19. Supplementary Figures 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
20. Supplementary Tables 1-2, Figures Legends 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
21. Data from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
22. Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia
23. The clinical impact of the molecular landscape of acute myeloid leukemia
24. Predicting Successful Hematopoietic Stem Cell Collection in Healthy Allogeneic Donors
25. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis
26. Minimal residual disease–directed therapy in acute myeloid leukemia
27. Radical surgery and venetoclax + azacitidine in an octogenarian with acute myeloid leukemia
28. Impact of Inotuzumb Ozogamicin on Outcome in Relapsed or Refractory Acute B-Lymphoblastic Leukemia Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation
29. Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
30. Atypical presentation of patients with chronic myeloid leukemia in chronic phase—Case report
31. Lesions learned from therapy-related acute myeloid leukemia
32. Advances in targeted therapy for acute myeloid leukaemia
33. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients
34. Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia
35. Atypical presentation of patients with chronic myeloid leukemia in chronic phase: Case report
36. Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD
37. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
38. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)
39. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)
40. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing
41. Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives
42. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
43. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies
44. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin
45. Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report
46. Antibody–drug conjugates in acute myeloid leukaemia: more research needed
47. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
48. Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia
49. Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease
50. Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.